Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: A validation study of the Gynecologic Oncology group criteria

Journal of Gynecologic Oncology

Volumn 26, Issue 1, 2015, Pages 32-39

  Kong, Tae Wook ^a,b   Chang, Suk Joon ^a,b   Paek, Jiheum ^a,b   Lee, Yonghee ^a,c   Chun, Mison ^a,d   Ryu, Hee Sug ^a,b  

^a Gynecologic Cancer Center   (South Korea)

^b Departments of Obstetrics and Gynecology   (South Korea)

^c Yonsei University   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Adjuvant; Chemotherapy; Disease free survival; Endometrial neoplasms; Radiotherapy; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENITAL SYSTEM DISEASE ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVERALL SURVIVAL; RETROSPECTIVE STUDY; VALIDATION STUDY; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84926359036     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2015.26.1.32     Document Type: Article

References (28)

1. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-1411.
2. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-751.
3. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of highintermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-823.
4. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-104.
5. Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 2012;124:31-35.
6. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995;58:198-201.
7. Sutton GP, Geisler HE, Stehman FB, Young PC, Kimes TM, Ehrlich CE. Features associated with survival and disease-free survival in early endometrial cancer. Am J Obstet Gynecol 1989;160:1385-1391.
8. Grigsby PW, Perez CA, Kuten A, Simpson JR, Garcia DM, Camel HM, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992;22:905-911.
9. Mundt AJ, Waggoner S, Yamada D, Rotmensch J, Connell PP. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol 2000;79:79-85.
10. Fleming ND, Lentz SE, Cass I, Li AJ, Karlan BY, Walsh CS. Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma? Gynecol Oncol 2011;120:189-912.
11. Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001;82:371-374.
12. Ahmed A, Zamba G, DeGeest K, Lynch CF. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992-2002. Gynecol Oncol 2008;111:35-40.
13. Truong PT, Kader HA, Lacy B, Lesperance M, MacNeil MV, Berthelet E, et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol 2005;28:157-164.
14. Briet JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 2005;96:799-804.
15. Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N, Thomas G, Covens A, et al. Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2008;129:912-917.
16. O'Brien DJ, Flannelly G, Mooney EE, Foley M. Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality. BJOG 2009;116:991-994.
17. Narayan K, Khaw P, Bernshaw D, Mileshkin L, Kondalsamy Chennakesavan S. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and highrisk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy. Int J Gynecol Cancer 2012; 22:260-226.
18. Weinberg LE, Kunos CA, Zanotti KM. Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk earlystage endometrioid endometrial cancer. Int J Gynecol Cancer 2013;23:1438-1445.
19. Honore LH, Hanson J. Statistical analysis of pathologic risk factors for intramyometrial lymphvascular space involvement in myoinvasive endometrial carcinoma. Int J Gynecol Cancer 2006;16:1330-1335.
20. Akbayir O, Corbacioglu A, Goksedef BP, Numanoglu C, Akca A, Guraslan H, et al. The novel criteria for predicting pelvic lymph node metastasis in endometrioid adenocarcinoma of endometrium. Gynecol Oncol 2012;125:400-403.
21. Chang SJ, Kong TW, Kim WY, Yoo SC, Yoon JH, Chang KH, et al. Lymph-vascular space invasion as a significant risk factor for isolated para-aortic lymph node metastasis in endometrial cancer: a study of 203 consecutive patients. Ann Surg Oncol 2011;18:58-64.
22. Gadducci A, Cosio S, Fabrini MG, Fanucchi A, Barsotti C, Cristofani R, et al. Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. Anticancer Res 2011;31:3483-3488.
23. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-838.
24. Kong TW, Paek J, Chang SJ, Chun M, Chang KH, Ryu HS. Com prehensive staging surgery including complete pelvic and para-aortic lymphadenectomy followed by adjuvant vaginal brachytherapy improves survival rates for intermediate-risk endometrial cancer patients. Gynecol Obstet Invest 2012;74:68-75.
25. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatinbased combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-233.
26. Kuoppala T, Maenpaa J, Tomas E, Puistola U, Salmi T, Grenman S, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemoradiotherapy. Gynecol Oncol 2008;110:190-195.
27. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer: results from two randomised studies. Eur J Cancer 2010;46:2422-2431.
28. Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, et al. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol 2014;132:50-54.